Here’s a breakdown of the citations and key findings from the provided text:
Key Findings:
* Lower GPRC5D expression in t(11;14) myeloma: Tumors with the t(11;14) translocation exhibit lower levels of GPRC5D mRNA.
* Reduced Chromatin Accessibility: scATAC-seq data shows decreased chromatin accessibility at the GPRC5D gene body, promoter, and key enhancer regions in t(11;14) tumors compared to those without the translocation.
* Long-range Chromatin Interactions: Hi-C analysis suggests a coordinated regulatory relationship between GPRC5D and HEBP1, and long-range interactions between EMP1 and GPRC5D potentially involving distal enhancer-promoter communication.
* B-cell like program: t(11;14) myeloma exhibits a B-cell like transcriptional and epigenetic program.
Citations (and what they support):
* 34: (Not explicitly stated what it supports in this excerpt)
* 35: supports the plasma-cell-restricted expression pattern of GPRC5D.Also cited in relation to GPRC5D being a target for immunotherapy.
* 36: Supports the plasma-cell-restricted expression pattern of GPRC5D.
* 37, 38, 39: Support the B cell-like transcriptional and epigenetic program associated with t(11;14) myeloma. Citation 39 specifically relates to the scRNA-seq and scATAC-seq data used in the study.
* 40: Describes the Peak2Gene analysis method used to identify key enhancer regions.
* 41: Describes the Hi-C analysis method used to study chromatin interactions.
In essence, the text describes research investigating why t(11;14) myeloma might be less responsive to therapies targeting GPRC5D. The findings suggest that reduced GPRC5D expression in these tumors is linked to epigenetic changes (reduced chromatin accessibility) and altered chromatin institution.
